NCT04425707 is a NA clinical trial of Ivermectin in Covid19, sponsored by Ministry of Health and Population, Egypt.

Who is sponsoring NCT04425707?

NCT04425707 is sponsored by Ministry of Health and Population, Egypt.

What drugs are being tested in NCT04425707?

Interventions in NCT04425707: Ivermectin.

Is NCT04425707 still recruiting?

NCT04425707 is currently status unknown. Last updated 11 June 2020.

Last reviewed 2020-06-11 · How we verify

NCT04425707

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivermectin In Treatment of COVID 19 Patients

Status unknown NA Last updated 11 June 2020

What this trial tests

NA trial testing Ivermectin in Covid19 in 100 participants. Status unknown.

Timeline

9 June 2020

Primary endpoint
1 July 2020

1 September 2020

Quick facts

Lead sponsor	Ministry of Health and Population, Egypt
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	9 June 2020
Primary completion	1 July 2020
Estimated completion	1 September 2020
Sites	1 location across Egypt

Drugs / interventions tested

Ivermectin (ivermectin) — full drug profile →

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

Ministry of Health and Population, Egypt

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Ivermectin for preventing and treating COVID-19.
Popp M, Stegemann M, Metzendorf MI, Gould S, et al · · 2021 · cited 102× · PMID 34318930 · DOI 10.1002/14651858.cd015017.pub2
Multi-omics-based identification of SARS-CoV-2 infection biology and candidate drugs against COVID-19.
Barh D, Tiwari S, Weener ME, Azevedo V, et al · · 2020 · cited 57× · PMID 33131530 · DOI 10.1016/j.compbiomed.2020.104051
Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
Kaur H, Shekhar N, Sharma S, Sarma P, et al · · 2021 · cited 52× · PMID 33389725 · DOI 10.1007/s43440-020-00195-y
Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA, Wagstaff KM. · · 2020 · cited 52× · PMID 32942671 · DOI 10.3390/cells9092100
Ivermectin for preventing and treating COVID-19.
Popp M, Reis S, Schießer S, Hausinger RI, et al · · 2022 · cited 30× · PMID 35726131 · DOI 10.1002/14651858.cd015017.pub3
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM. · · 2021 · cited 26× · PMID 33341233 · DOI 10.1016/j.bbrc.2020.10.042
The Role of Protein Disorder in Nuclear Transport and in Its Subversion by Viruses.
Wubben JM, Atkinson SC, Borg NA. · · 2020 · cited 23× · PMID 33321790 · DOI 10.3390/cells9122654
COVID-19 associated complications and potential therapeutic targets.
Monpara JD, Sodha SJ, Gupta PK. · · 2020 · cited 21× · PMID 32926918 · DOI 10.1016/j.ejphar.2020.173548

Verify or expand the search:

Other trials of Ivermectin

Trials testing the same drug.

NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other Ministry of Health and Population, Egypt trials

Trials by the same sponsor.

NCT06148805 — Effect of Pilates Exercises and Diaphragm Manual Therapy Techniques in Rotator Cuff Tendinopathy · NA · unknown
NCT06002256 — Mostafa Maged Maneuver in Comparison With Bimanual Uterine Compression to Control Post-partum Hemorrhage · NA · completed
NCT06159959 — Carbetocin in the Prevention of Primary Postpartum Haemorrhage · completed
NCT06801106 — Acapella Versus Lung Flute in Treatment of COPD Patients the Study Aims to Identify the Preference Between the Two Devic · NA · completed
NCT04816942 — Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04425707 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ministry of Health and Population, Egypt
Last refreshed: 11 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04425707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing